Many people who have lived through a traumatic event such as a natural disaster or a serious accident experience some level of post-traumatic stress disorder (PTSD). It can result in symptoms ranging from anxiety to self-harm. PTSD commonly impacts those who have faced war and combat, often leaving veterans struggling with mental health. A staggering report by the Department of Veterans Affairs revealed that every 72 seconds in the United States, a veteran takes their own life. Despite how common and serious this condition can be, treatments are limited and there isn't a single pharmaceutical drug on the market to treat it.

Mydecine Innovations Group (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) is working to change this. The emerging biopharma and life sciences company has been quietly working to build what might be one of the most innovative health products in recent years. They are using cutting edge clinical research to unlock the healing powers of psychedelics and turning what was once thought of as "alternative treatments'' into the future of modern medicine.

Psychedelic medicine: a groundbreaking therapy for PTSD

Originally founded to examine the unique compounds in mushrooms, Mydecine has now become the first company to run clinical trials for the treatment of PTSD with psychedelics, focusing on veteran, EMS and first responder communities. They also happen to be one of only four companies with approval to carry out a Phase 2 clinical trial for the treatment of PTSD with psychotherapy. Currently, Mydecine has seven clinical trials in progress throughout Canada, the USA and the EU.

Beyond clinical research, Mydecine Innovations Group is making significant progress in the world of commercial psychedelics. This year they became the first company to obtain CGMP status (clearance) to produce, sell and export medical psilocybin. Mydecine is rapidly developing psychedelic medicines and mushroom products for the professional and consumer healthcare markets.

2021 is an exciting year for Mydecine

Having steadily raised capital, been selected for inclusion in the Horizons Psychedelic ETF, and completed the first-ever international export of psilocybin mushrooms, Mydecine has started 2021 off on strong footing.

The upcoming year will clearly be a busy one as Mydecine has their sights set on the Nasdaq. This will provide exposure to a new set of institutional and retail investors. To assist in this process, Mydecine has hired a new CMO and added some impressive names to their board of directors.

Developing alongside Mydecine's clinical research and commercialization is their innovative digital health delivery platform, Mindleap. This telemedicine application was designed by clinical psychologists and neuroscientists and has been built specifically for the psychedelic medicine industry. It is the first digital health platform that combines telehealth for mental health with mood, emotion and habit tracking.

The future of the psychedelic treatment industry

PTSD, as well as other mental health disorders such as depression and anxiety, are conditions that impact the lives of millions of Americans every day. With few solutions, an increasing number of people are finding support in psychedelic and integrative medicine than ever before - particularly when it comes to treating their mental health. 

The research and promising developments have indicated that psychedelics have untapped potential as a treatment for enhancing mental health and wellbeing. This is a sector of modern medicine that will undoubtedly continue to see major growth in the decades to come, and Mydecine is excited to be pushing the industry forward.